Myeloma Investment Fund Invests in Dynamic Cell Therapies to Help Fuel Novel CAR-T-Cell Technologies
Summary
These technology platforms will improve the safety and efficacy of CAR-T cell therapies and have immediate application for patients with hematological cancers, including multiple myeloma. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches and empower myeloma patients and the broader community with information and resources to extend their lives. Since our inception, the MMRF has committed over $600 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.orgFor MMRF or MIF media inquiries, please contact: Anna Otis, Manager, Brand Marketing, [email protected]Dynamic Cell Therapies (DCT) is a pre-clinical stage biopharmaceutical company engineering CAR-T cells to address unmet medical needs for patients with cancers and autoimmune diseases. Private cytokine signaling can enhance memory populations, which increases CAR-T cells persistence and durable responses.